natgillin/translations-raw huggingface dataset:
Relapsed/Refractory follicular lymphoma
Ponovitev folikularnih limfomov ali neodzivna bolezen
Relapsed/refractory Ph+ ALL: When imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30 % (9 % complete) and a major cytogenetic response rate of 23 %. (Of note, out of the 411 patients, 353 were treated in an expanded access program without primary response data collected.) The median time to progression in the overall population of 411 patients with relapsed/refractory Ph+ ALL ranged from 2.6 to 3.1 months, and median overall survival in the 401 evaluable patients ranged from 4.9 to 9 months.
Relaps/neodzivna Ph+ ALL: Zdravljenje z imatinibom kot edinim zdravilom pri bolnikih z relapsom/neodzivno Ph+ ALL je povzročilo pri 53 od 411 za oceno odziva primernih bolnikov stopnjo hematološkega odziva 30 % (v 9 % popolni hematološki odziv) in stopnjo pomembnega citogenetičnega odziva 23 %. (V pojasnilo: od 411 bolnikov jih je bilo 353 zdravljenih v programu razširjenega dostopa brez zbranih podatkov o primarnem odzivu.) Mediani čas do napredovanja bolezni je bil pri vseh 411 bolnikih z relapsom/neodzivno Ph+ ALL v obsegu od 2,6 do 3,1 meseca, mediano preživetje nasploh pa je bilo pri 401 za oceno primernih bolnikov v obsegu od 4,9 do 9 mesecev.
Relapsed/refractory Ph+ ALL: When imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30% (9% complete) and a major cytogenetic response rate of 23%. (Of note, out of the 411 patients, 353 were treated in an expanded access program without primary response data collected.) The median time to progression in the overall population of 411 patients with relapsed/refractory Ph+ ALL ranged from 2.6 to 3.1 months, and median overall survival in the 401 evaluable patients ranged from 4.9 to 9 months.
Relaps/neodzivna Ph+ ALL: Zdravljenje z imatinibom kot edinim zdravilom pri bolnikih z relapsom/neodzivno Ph+ ALL je povzročilo pri 53 od 411 za oceno odziva primernih bolnikov stopnjo hematološkega odziva 30 % (v 9 % popolni hematološki odziv) in stopnjo pomembnega citogenetičnega odziva 23 %. (V pojasnilo: od 411 bolnikov jih je bilo 353 zdravljenih v programu razširjenega dostopa brez zbranih podatkov o primarnem odzivu.) Mediani čas do napredovanja bolezni je bil pri vseh 411 bolnikih z relapsom/neodzivno Ph+ ALL v obsegu od 2,6 do 3,1 meseca, mediano preživetje nasploh pa je bilo pri 401 za oceno primernih bolnikov v obsegu od 4,9 do 9 mesecev.
Relapser
Osebe z relapsom
relapsers Outcome for subjects without SVR12
Izid pri preiskovancih brez SVR12
Relapsers† in the parent study (29)
Bolniki z recidivom† v predhodni študiji (29)
Relapses were reduced by about 30% over two years for both Rebif 22 and 44 micrograms compared with placebo, and by 22% (Rebif 22 micrograms) and 29% (Rebif 44 micrograms) over four years.
V dveh letih je zdravilo Rebif v odmerku 22 in 44 mikrogramov zmanjšalo število zagonov za 30 % v primerjavi s placebom, v štirih letih pa za 22 % (zdravilo Rebif v odmerku 22 mikrogramov) in 29 % (zdravilo Rebif v odmerku 44 mikrogramov).
Relapse†
ponovitev bolezni
Relapse†
Recidiv
Relapse† %(n/N)
Recidiv† % (n/N)
Relapsing
Ponovitev
Relapsing- Remitting Multiple Sclerosis
recidivno- remitentna multipla skleroza
Related adverse reactions of CTC grade 3 and 4 occurred in 37% of patients in clinical trials.
Do povezanih neželenih reakcij CTC stopnje 3 in 4 je prišlo pri 37 % bolnikov v kliničnih preskušanjih.
related AIS
povezana s HPV 16/18
related CIN 2/3 or AIS
AIS, povezana s HPV 16/18
related CIN 3
povezana s HPV 16/18
related death
povezana smrt
Related discontinuations
povezane prekinitve
related GI reactions
gastrointestinalne (GI)
related GI reactions
in perforacije prebavil)
Related to central venous access devices (CVAD)
V zvezi s centralnim venskim dostopom (CVAD)
Related to MACI:
Zapleti, povezani z zdravilom MACI:
relationship of ivabradine in paediatric chronic heart failure patients aged 6 months to less than 18 years is similar to the PK/PD relationship described in adults.
PK/PD razmerje ivabradina pri pediatričnih bolnikih s kroničnim srčnim popuščanjem, starih od 6 mesecev do manj kot 18 let, je podobno PK/PD razmerju, ki so ga opisali pri odraslih.
Relative % predicted
Relativna sprememba napovedane % ravni
Relative AUC and Cmax of aliskiren in subjects with renal impairment ranged between
Relativne AUC in Cmax aliskirena pri bolnikih z okvaro ledvic so se gibale med
Relative bioavailability between the capsules and powder for oral suspension in sachet formulations has been studied in healthy male volunteers after a 1,000 mg single oral administration.
Relativna biološka uporabnost kapsul v primerjavi s praškom za peroralno suspenzijo v vrečkah je bila predmet študije pri zdravih prostovoljcih moškega spola, ki so prejeli enkraten peroralni odmerek 1000 mg.
Relative change from Baseline to Day 28 LS Mean (SE)
Relativna sprememba od izhodišča do 28. dneva Povprečje po metodi najmanjših kvadratov (LS, least squares) (SE)
Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms.
Sorazmerno velika preveliko odmerjanje (200 mg dnevno oziroma 105 mg dnevno, tri dni) je bilo povezano bodisi samo s simptomi utrujenosti, šibkosti in/ali driske bodisi je bilo brez simptomov.
Relative potency (ELISA test) by comparison with a reference vaccine
relativna učinkovitost (preskus ELISA) v primerjavi z referenčnim cepivom
Relative potency (ELISA).
3,34 IE50
Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in calves.
Relativna potenca pri testu potence pri miših v primerjavi z referenčnim cepivom, ki je bilo učinkovito pri teletih.
Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in cattle.
Relativna potenca pri testu potence pri miših v primerjavi z referenčnim cepivom, ki je bilo učinkovito pri govedu.
Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep.
Relativna potenca pri testu potence pri miših v primerjavi z referenčnim cepivom, ki je bilo učinkovito pri ovcah.
Relative Risk
Relativno tveganje
Relative Risk
relativno tveganje (95 % IZ)
Relative risk (95% CI)
Relativno tveganje (95 % IZ)
Relative risk (95% CI) of GvHD and TRM
Relativno tveganje (95 % IZ) pri GvHD in TRM
Relative risk (95% CI) of GvHD and TRM following treatment with G-CSF after bone marrow (BM) transplantation
Relativno tveganje (95- IZ) za pojav reakcije presadka proti gostitelju (GvHD) in TRM po zdravljenju z G-CSF po presaditvi kostnega mozga
Relative risk (95% CI) of GvHD and TRM following treatment with G-CSF after bone marrow transplantation
Relativno tveganje (95-% IZ) za GvHD in TRM po zdravljenju z G-CSF po presaditvi kostnega mozga
Relative Risk [95% CI]
relativno tveganje [95% CI]
Relative risk reduction
relativno zmanj- šanje tveganja
Relative risk reduction (95% CI) vs. placebo
Relativno zmanjšanje tveganja (95% CI) v primerjavi s placebom
Relative Risk Reduction (97.5% CI)
Zmanjšanje relativnega tveganja (97,5-% IZ)
Relative risk reduction in fracture incidence
relativno znižanje tveganja za zlome
Relative Risk Reduction New morphometric vertebral fractures
zmanjšanje relativnega tveganja za nove zlome vretenc (določeno morfometrično)
Relative to fasting conditions, administration of an early capsule formulation of idelalisib with a high- fat meal resulted in no change in Cmax and a 36% increase in mean AUCinf.
V primerjavi s pogoji na tešče dajanje zgodnje oblike kapsule idelaliziba z obrokom z visoko vsebnostjo maščob ni povzročilo spremembe vrednosti Cmax, povprečna vrednost AUCinf pa se je povečala za 36 %.
Relative to fasting conditions, the administration of a single dose of elbasvir/grazoprevir with a high- fat (900 kcal, 500 kcal from fat) meal to healthy subjects resulted in decreases in elbasvir AUC0-inf and Cmax of approximately 11 % and 15 %, respectively, and increases in grazoprevir AUC0-inf and Cmax of approximately 1.5-fold and 2.8-fold, respectively.
V primerjavi z uporabo na tešče je uporaba enkratnega odmerka elbasvirja/grazoprevirja z zelo mastnim obrokom (900 kcal, 500 kcal iz maščob) pri zdravih preiskovancih zmanjšala AUC0-inf elbasvirja za približno 11 % in njegovo Cmax za približno 15 % ter povečala AUC0-inf grazoprevirja za približno 1,5-krat in njegovo Cmax za približno 2,8-krat.
Relative to fasting conditions, the administration of Odefsey to healthy adult subjects with food resulted in increased rilpivirine exposure (AUC) by 13-72%.
Relativno glede na pogoje na tešče, je dajanje zdravila Odefsey zdravim odraslim osebam z obrokom, povzročilo večjo izpostavljenost rilpivirinu (AUC) za 13–72 %.
Relative to fasting conditions, the administration of Odefsey to healthy adult subjects with food resulted in increased tenofovir alafenamide exposure (AUC) by 45-53%.
Relativno glede na pogoje na tešče, je dajanje zdravila Odefsey zdravim odraslim osebam z obrokom, povzročilo večjo izpostavljenost alafenamidtenofoviratu (AUC) za 45–53 %.
Relative to fasting conditions, the administration of tenofovir alafenamide with a high fat meal (~800 kcal, 50% fat) resulted in a decrease in tenofovir alafenamide Cmax (15-37%) and an increase in AUClast (17-77%).
Relativno glede na pogoje na tešče je dajanje alafenamidtenofovirata z obrokom z veliko vsebnostjo maščob (~ 800 kcal, 50 % maščobe) povzročilo zmanjšanje vrednost Cmax (15–37 %) in povečanje vrednost AUClast (17–77 %) za alafenamidtenofovir.
Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).
V primerjavi z zdravljenjem z nivolumabom v monoterapiji so pri zdravljenju z nivolumabom v kombinaciji z ipilimumabom podaljšanje preživetja brez napredovanja bolezni (PFS - progression-free survival) ugotovili le pri bolnikih z nizko ekspresijo PD-L1 tumorja (glejte poglavji 4.4 in 5.1).
Relative to non-obese subjects daptomycin systemic exposure measured by AUC was about 28% higher in moderately obese subjects (Body Mass Index of 25-40 kg/m2) and 42% higher in extremely obese subjects (Body Mass Index of > 40 kg/m2).
V primerjavi z osebami, ki niso debele, je bila sistemska izpostavljenost daptomicinu, merjena v obliki AUC, večja za okrog 28 % pri srednje debelih osebah (indeks telesne mase 25-40 kg/m2) in večja za 42 % pri izredno debelih osebah (indeks telesne mase > 40 kg/m2).
Relative to placebo, FABLYN significantly decreased total cholesterol, LDL cholesterol, LDL-associated apolipoprotein B-100, and high sensitivity C-reactive protein (median changes -10.4%, -15.8%, -11.8%, -12.5%, respectively); no significant changes versus placebo were seen for HDL cholesterol or VLDL cholesterol.
V primerjavi s placebom je zdravilo FABLYN signifikantno zižalo celotni holesterol, LDL holesterol, z LDL povezani apolipoprotein B-100 in C- reaktivni protein z veliko občutljivostjo (mediane spremembe -10,4 %, -15,8 %, -11,8 % oziroma - 12,5 %); pri HDL holesterolu in VLDL holesterolu signifikantnih sprememb v primerjavi s placebom niso našli.
Relative to placebo, the decline in quality of life was slower for Xofigo during the on-treatment period as measured by EQ-5D utility index score (-0.040 versus – 0.109; p=0.001), EQ-5D self-reported Visual Analogue health status scores (VAS) (-2.661 versus -5.860; p=0.018) and the FACT P total score (-3.880 versus -7.651, p=0.006) but did not reach published minimally important differences.
V primerjavi s placebom, se je kakovost življenja poslabševala počasneje med zdravljenjem z zdravilom Xofigo, glede na rezultate izpolnjenega vprašalnika EQ-5D (-0,040 v primerjavi z -0,109; p = 0,001), vprašalnika za samooceno vizualno analognega zdravstvenega stanja EQ-5D VAS (-2,661 v primerjavi z -5,860; p = 0,018) ter skupnega rezultata vprašalnika FACT-P (-3,880 v primerjavi z -7,651; p = 0,006), vendar ni dosegla objavljenih najmanjših značilnih razlik.
Relative to placebo, Xarelto significantly reduced the primary composite endpoint of CV death, MI or stroke.
V primerjavi s placebom je zdravilo Xarelto pomembno zmanjšalo primarni sestavljen končni izid (kardiovaskularna smrt, miokardni infarkt ali možganska kap).
Relative to subjects with normal renal function, velpatasvir AUCinf was 50% higher in subjects with severe renal impairment (see section 4.2).
V primerjavi z osebami z normalnim delovanjem ledvic je bila vrednost AUCinf za velpatasvir za 50 % višja pri osebah s hudo ledvično okvaro (glejte poglavje 4.2).
Relative to the adverse reactions noted in section b.
Poleg neželenih učinkov, ki so navedeni v poglavju b.
Relative to the AUC of TMZ, the exposure to MTIC and AIC is ~ 2.4% and 23%, respectively.
Glede na vrednost AUC temozolomida je izpostavljenost MTIC približno 2,4-odstotna, izpostavljenost AIC pa 23-odstotna.
Relative to the AUC of TMZ, the exposure to MTIC and AIC is ~ 2.4% and 23%, respectively.
Glede na vrednost AUC za TMZ je izpostavljenost MTIC in AIC ~ 2,4 % oziroma 23 %.
Relatively few patients less than 5 years postmenopausal and 45-54 years of age were enrolled in the phase III study (2-3%).
V študiji faze III je bilo vključenih relativno malo bolnic, pri katerih je od menopavze minilo manj kot 5 let in ki so bile stare 45-54 let (2-3%).
RELEASE
SPROŠČANJE SERIJE
release button dose counter
sprožilni gumb števec odmerkov
Release liner
Zaščitna plast
Release liner Polyester
Opna za nadziranje sproščanja: poliester
Release liner: polyester film, fluoropolymer-coated.
Opna za nadziranje sproščanja: poliestrski film obložen s fluoro-polimerom.
Release liner: Transparent fluoropolymer coated polyester film.
Zaščitna plast: poliestrski film, prekrit s prozornim fluoropolimerom
Release liner: Transparent fluoropolymer coated polyester film.
Zaščitna plast: poliestrski film, prekrit s prozornim fluoropolimerom.
Release residual air (prime the pen)
Sprostite odvečen zrak (pripravite peresnik)
Release the button immediately
Gumb takoj izpustite
Release the dose setting knob.
Izpustite gumb za nastavitev odmerka.
RELEASE the green button
SPROSTITE zeleni gumb
RELEASE the orange button
SPROSTITE oranžni gumb.
Release the pinched skin and pull the needle straight out.
Izpustite stisnjeno kožo in iglo izvlecite naravnost iz kože.
Release the plunger, allowing the needle guard to protect the needle.
Sprostite bat in s tem bo varovalo za iglo zaš itilo iglo.
Release the plunger.
Spustite bat.
Release the skin fold and gently pull the needle out.
Spustite kožno gubo in nežno izvlecite iglo.
release the skin use this free hand to hold on to the main part of the syringe – this will help steady it and stop it from moving.
to prosto roko primite osrednji del injekcijske brizge – tako jo lažje držite pri miru in preprečite premikanje.
Release the skin with the first hand
Spustite kožo s prvo roko.
Release the skin with the first hand.
Kožo spustite.
Release the skin with the first hand.
S prvo roko sprostite kožo.
Release your thumb from the plunger
Palec spustite z bata.
release)/600 mg once daily]
sproščanje)/600 mg enkrat na dan]
Releasing an egg too early (premature ovulation)
prezgodnja sprostitev jajčeca (prezgodnja ovulacija)
relevance of the
znižanja C8ur boceprevirja
relevance of these findings has
Klinični pomen teh ugotovitev še ni znan.
relevance of these findings has
pomen teh ugotovitev še ni znan.
relevant (as
pomembni
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Pomembni primeri so citomegalovirusni retinitis, generalizirane in/ali žariščne okužbe z mikobakterijami ter s Pneumocystis carinii povzročena pljučnica.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Ustrezni primeri so citomegalovirusni renitis, generalizirane in/ali žariščne okužbe z mikobakterijami in pljučnica, povzročena s Pneumocystis carinii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis jiroveci pneumonia (formerly known as Pneumocystis carinii pneumonia).
Ustrezni primeri so citomegalovirusni retinitis, generalizirane in/ali žariščne okužbe z mikobakterijami in s Pneumocystis jiroveci povzročena pljučnica (pred tem znana kot s Pneumocystis carinii povzročena pljučnica).
Relevant information (e.g. seriousness, severity, frequency, time to onset, reversibility of the AE as applicable) for the following safety concerns:
Relevantne podatke (npr. o resnosti, jakosti, pogostnosti, času pojava, reverzibilnosti neželenega učinka, kot je primerno) za naslednja varnostna tveganja:
Relevant information about the safety concern of Concomitant administration of Ganciclovir and Valganciclovir
Pomembne informacije glede varnosti sočasne uporabe ganciklovirja in valganciklovirja
Relevant information about the safety concerns of Graft versus Host Disease (GvHD)
Pomembne informacije glede varnosti pri reakciji presadka proti gostitelju (GvHD)
Relevant information on the risk of bleeding
pomembne informacije o tveganju krvavitev;
reliable method of contraception (see sections 4.4 and 4.6).
zanesljivo metodo kontracepcije (glejte poglavji 4.4 in 4.6).
Relief of pain and inflammation associated with osteoarthritis: 6 months.
Lajšanje bolečine in vnetij povezanih z osteoartritisom: 6 mesecev.
Relief of post-operative pain following dehorning in calves.
Za lajšanje pooperativne bolečine po odstranitvi rogov teletom.
Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.
Olajšanje simptomov traja ves dan in vam pomagala, da lahko znova opravljate vsakodnevne dejavnosti in spite.
Relieves heartburn
Olajša zgago.
Relieves heartburn.
Olajša zgago.
Relistor 12 mg Injection Methylnaltrexone bromide SC
Relistor 12 mg injekcija metilnaltreksonijev bromid s.c.
Relistor 12 mg solution for injection in pre-filled syringe
Relistor 12 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
Relistor 12 mg solution for injection in pre-filled syringe Methylnaltrexone bromide
Relistor 12 mg raztopina za injiciranje v napolnjeni injekcijski brizgi metilnaltreksonijev bromid
Relistor 12 mg/0.6 mL solution for injection
Relistor 12 mg/0,6 ml raztopina za injiciranje
Relistor 12 mg/0.6 mL solution for injection Methylnaltrexone bromide
Relistor 12 mg/0,6 ml raztopina za injiciranje
Relistor 8 mg injection Methylnaltrexone bromide SC
Relistor 8 mg injekcija metilnaltreksonijev bromid s.c.
Relistor 8 mg solution for injection in pre-filled syringe
Relistor 8 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
Relistor 8 mg solution for injection in pre-filled syringe Methylnaltrexone bromide
Relistor 8 mg raztopina za injiciranje v napolnjeni injekcijski brizgi metilnaltreksonijev bromid
Relistor 8 mg solution for injection in pre-filled syringe Relistor 12 mg solution for injection in pre-filled syringe Methylnaltrexone bromide
Relistor 8 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Relistor 12 mg raztopina za injiciranje v napolnjeni injekcijski brizgi metilnaltreksonijev bromid
Relistor contains an active substance called methylnaltrexone bromide which acts by blocking the side effects of opioid pain medicines that affect the bowel.
Zdravilo Relistor vsebuje zdravilno učinkovino, imenovano metilnaltreksonijev bromid, ki deluje tako, da zavira neželene učinke opioidnih zdravil na črevesju
Relistor contains an active substance called methylnaltrexone bromide which acts by blocking the side effects of opioid pain medicines that affect the bowel.
Zdravilo Relistor vsebuje zdravilno učinkovino, imenovano metilnaltreksonijev bromid, ki deluje tako, da zavira neželene učinke opioidnih zdravil na črevesju.
Relistor has also been compared with placebo in 496 patients with constipation caused by opioids, but no advanced illness.
Zdravilo Relistor so s placebom primerjali tudi pri 496 bolnikih, ki so bili zaprti zaradi jemanja opioidov, a niso imeli napredovale bolezni.
Relistor has been compared with placebo (a dummy treatment) in two main studies involving a total of 288 patients with an advanced illness and constipation caused by opioids.
Zdravilo Relistor so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, v kateri je bilo vključenih skupaj 288 bolnikov z napredovalo boleznijo in zaprtjem, ki ga povzroča jemanje opioidov.
Relistor is a solution for injection that contains the active substance methylnaltrexone bromide.
Relistor je raztopina za injiciranje, ki vsebuje zdravilno učinkovino metilnaltreksonijev bromid.
Relistor is not recommended for patients who have very severe kidney problems that require dialysis (a blood clearance technique).
Zdravilo Relistor ni priporočljivo za bolnike, ki imajo hude težave z jetri ali potrebujejo dializo (tehniko čiščenja krvi).
Relistor is used to treat the constipation caused by opioids (painkillers that are related to morphine and used to treat moderate to severe pain due to long-term or advanced diseases) in adults (aged 18 years or over) when the response to laxative medicines has not been sufficient.
Zdravilo Relistor se uporablja za zdravljenje zaprtosti zaradi opioidov (zdravil proti bolečinam, ki vsebujejo morfin in se uporabljajo za zdravljenje zmerne do hude bolečine zaradi dolgotrajne ali napredovale bolezni) pri odraslih (starejših od 18 let), kadar odziv na odvajalna zdravila ni zadosten.
Relistor must not be used in patients whose bowel is blocked or who have a condition that needs immediate bowel surgery.
Zdravila Relistor ne smejo uporabljati bolniki z zaprtim črevesjem ali tisti, katerih stanje zahteva takojšnjo operacijo črevesja.
Relistor pre-filled syringe
napolnjeno injekcijsko brizgo zdravila Relistor
Relistor was more effective than placebo in stimulating the bowels to open in patients with an advanced illness.
Zdravilo Relistor je bilo pri spodbujanju odvajanja blata pri bolnikih z napredovalo boleznijo učinkovitejše od placeba.
Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed
Relvar Ellipta 184 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni.
Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate /vilanterol
Relvar Ellipta 184 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni flutikazonfuroat/vilanterol
Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Relvar Ellipta 184 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni flutikazonfuroat/vilanterol
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed
Relvar Ellipta 92 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate /vilanterol
Relvar Ellipta 92 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni flutikazonfuroat/vilanterol
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Relvar Ellipta 92 mikrogramov/22 mikrogramov prašek za inhaliranje, odmerjeni flutikazonfuroat/vilanterol
Relvar Ellipta 92/22 microgram (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) can be used for the treatment of both asthma and COPD, while Relvar Ellipta 184/22 microgram (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol) can only be used for the treatment of asthma.
Zdravilo Relvar Ellipta 92/22 mikrogramov (92 mikrogramov flutikazon furoata in 22 mikrogramov vilanterola) se lahko uporablja za zdravljenje astme in tudi kronične obstruktivne pljučne bolezni, medtem ko se lahko zdravilo Relvar Ellipta 184/22 mikrogramov (184 mikrogramov flutikazon furoata in 22 mikrogramov vilanterola) uporablja samo za zdravljenje astme.